272 related articles for article (PubMed ID: 27886818)
21. Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Jiang M; You JH
Expert Opin Pharmacother; 2015 Apr; 16(5):771-9. PubMed ID: 25660101
[TBL] [Abstract][Full Text] [Related]
22. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
[TBL] [Abstract][Full Text] [Related]
23. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
[TBL] [Abstract][Full Text] [Related]
24. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
25. CYP2C19 genotype-directed P
Stys TP; Gedela M; Gowda SN; Bares V; Fanta L; Petrasko M; Hajek C; Larson E; Stys AT
Indian Heart J; 2021; 73(3):281-288. PubMed ID: 34154743
[TBL] [Abstract][Full Text] [Related]
26. Association between the microarray-based CYP2C19 genotyping assay and the platelet function test in cardiovascular patients receiving clopidogrel.
Choi JL; Kim BR; Kim JE; Woo KS; Kim KH; Kim JM; Kim MH; Han JY
Int J Lab Hematol; 2014 Oct; 36(5):e80-3. PubMed ID: 24589079
[No Abstract] [Full Text] [Related]
27. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
Ueno T; Koiwaya H; Sasaki KI; Katsuki Y; Katsuda Y; Murasato Y; Shimamatsu J; Umeji K; Otsuka Y; Kawasaki T; Shibata Y; Fukumoto Y
Cardiovasc Interv Ther; 2017 Oct; 32(4):341-350. PubMed ID: 27488859
[TBL] [Abstract][Full Text] [Related]
28. Role of genetic testing in patients undergoing percutaneous coronary intervention.
Moon JY; Franchi F; Rollini F; Rivas Rios JR; Kureti M; Cavallari LH; Angiolillo DJ
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):151-164. PubMed ID: 28689434
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population.
Bin Sayeed MS; Hasan Apu MN; Munir MT; Ahmed MU; Islam MS; Haq MM; Ahsan CH; Rashid MA; Shin JG; Hasnat A
Clin Exp Pharmacol Physiol; 2015 May; 42(5):451-7. PubMed ID: 25800075
[TBL] [Abstract][Full Text] [Related]
30. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.
Borse MS; Dong OM; Polasek MJ; Farley JF; Stouffer GA; Lee CR
Pharmacogenomics; 2017 Aug; 18(12):1155-1166. PubMed ID: 28745582
[TBL] [Abstract][Full Text] [Related]
31. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.
Collet JP; Hulot JS; Cuisset T; Rangé G; Cayla G; Van Belle E; Elhadad S; Rousseau H; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Barthélémy O; Beygui F; Silvain J; Vicaut E; Montalescot G;
Eur J Clin Pharmacol; 2015 Nov; 71(11):1315-24. PubMed ID: 26265231
[TBL] [Abstract][Full Text] [Related]
32. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
[TBL] [Abstract][Full Text] [Related]
33. Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.
AlMukdad S; Elewa H; Arafa S; Al-Badriyeh D
Int J Cardiol; 2021 May; 331():27-34. PubMed ID: 33535078
[TBL] [Abstract][Full Text] [Related]
34. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
Roberts JD; Wells GA; Le May MR; Labinaz M; Glover C; Froeschl M; Dick A; Marquis JF; O'Brien E; Goncalves S; Druce I; Stewart A; Gollob MH; So DY
Lancet; 2012 May; 379(9827):1705-11. PubMed ID: 22464343
[TBL] [Abstract][Full Text] [Related]
35. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.
Yang Y; Lewis JP; Hulot JS; Scott SA
Expert Opin Drug Metab Toxicol; 2015; 11(10):1599-617. PubMed ID: 26173871
[TBL] [Abstract][Full Text] [Related]
36. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.
Bonello L; Armero S; Ait Mokhtar O; Mancini J; Aldebert P; Saut N; Bonello N; Barragan P; Arques S; Giacomoni MP; Bonello-Burignat C; Bartholomei MN; Dignat-George F; Camoin-Jau L; Paganelli F
J Am Coll Cardiol; 2010 Nov; 56(20):1630-6. PubMed ID: 20708365
[TBL] [Abstract][Full Text] [Related]
37. Genetic considerations.
Price MJ
Adv Cardiol; 2012; 47():100-13. PubMed ID: 22906906
[TBL] [Abstract][Full Text] [Related]
38. Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?
Zeb I; Krim N; Bella J
Expert Rev Cardiovasc Ther; 2018 May; 16(5):369-377. PubMed ID: 29589775
[TBL] [Abstract][Full Text] [Related]
39. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
Price MJ; Tantry US; Gurbel PA
Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
[TBL] [Abstract][Full Text] [Related]
40. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
